Compare Summit Therapeutics Inc (SMMT) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Teucrium Wheat Fund — how do they compare? Summit Therapeutics Inc trades at $14.65 (market cap $10.48B), while Teucrium Wheat Fund trades at $25.21. The key difference: Teucrium Wheat Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | WEAT | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $29.32 | $25.49 |
52-Week Low | $13.05 | $19.88 |
Enterprise Value | $9.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
WEAT trades at $24.99, down 1.03% in the last session, with technical indicators showing a mixed but overall bullish bias. The USDA's reduced 2026 wheat production forecast to 1.56 billion bushels (WSJ, 2026-05-12) and recent wheat price volatility highlight fundamental supply-side influences. Moving averages signal strong bullish momentum, though oscillators indicate near-term overbought conditions.
The outlook for WEAT is cautiously optimistic, driven by agricultural commodity trends and supportive technicals. Key opportunities include exposure to wheat price appreciation, but risks involve weather impacts on crops, inflation fluctuations, and competitive ETF pressure as noted in recent coverage (24/7 Wall Street, 2026-05-16).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
